Annual percent change by component in British Columbia*
| Route of administration | Component; % change (95% CI) | ||||
|---|---|---|---|---|---|
| Total expenditure per capita | Cancer incidence per capita† | Users per incident case | Prescriptions per user | Cost per prescription | |
| Total | 6.6 (5.4 to 7.7) | −0.4 (−1.1 to 0.3) | 1.4 (0.8 to 2.1) | 2.2 (1.7 to 2.7) | 3.2 (2.5 to 3.9) |
| Oral | 13.1 (10.7 to 15.6) | −0.4 (−1.1 to 0.3) | 2.0 (1.4 to 2.6) | 3.0 (2.7 to 3.3) | 8.1 (6.0 to 10.2) |
| Intravenous/other | 3.8 (2.7 to 5.0) | −0.4 (−1.1 to 0.3) | 1.5 (0.8 to 2.2) | 1.5 (1.0 to 2.0) | 1.2 (0.6 to 1.9) |
| Oral; cancer site | |||||
| Breast | −11.4 (−17.8 to −4.5) | 1.1 (0.1 to 2.2) | 0.0 (−1.1 to 1.0) | 0.9 (0.4 to 1.3) | −13.0 (−19.1 to −6.6) |
| Colorectum | 5.7 (3.4 to 8.2) | 0.3 (−0.4 to 0.9) | 3.4 (1.7 to 5.1) | 2.8 (1.6 to 3.9) | −0.7 (−1.6 to 0.3) |
| Lung | 12.6 (9.7 to 15.6) | −1.6 (−2.4 to −0.8) | 8.5 (6.3 to 10.7) | 1.3 (0.2 to 2.4) | 4.0 (2.7 to 5.4) |
| Prostate | 26.4 (9.3 to 46.2) | −4.0 (−5.7 to −2.4) | 3.3 (1.8 to 4.8) | 5.7 (4.3 to 7.2) | 20.6 (4.8 to 38.7) |
| Other | 19.7 (15.1 to 24.4) | 0.5 (−0.3 to 1.3) | 3.2 (2.2 to 4.1) | 4.3 (3.6 to 4.9) | 10.7 (7.2 to 14.3) |
| Intravenous/other; cancer site | |||||
| Breast | −1.3 (−2.8 to 0.2) | 1.1 (0.1 to 2.2) | 0.9 (−0.3 to 2.0) | −0.6 (−1.1 to −0.1) | −2.6 (−3.4 to −1.8) |
| Colorectum | 6.1 (3.0 to 9.3) | 0.3 (−0.4 to 0.9) | 2.6 (1.4 to 3.8) | −0.2 (−1.0 to 0.7) | 3.4 (1.2 to 5.7) |
| Lung | 11.7 (8.2 to 15.3) | −1.6 (−2.4 to −0.8) | 1.0 (−0.4 to 2.4) | 0.7 (0.5 to 0.9) | 11.6 (8.5 to 14.7) |
| Prostate | −2.5 (−3.1 to −2.0) | −4.0 (−5.7 to −2.4) | 2.8 (1.6 to 3.9) | 1.3 (1.0 to 1.6) | −2.4 (−2.9 to −1.8) |
| Other | 8.0 (6.5 to 9.5) | 0.5 (−0.3 to 1.3) | 2.3 (1.2 to 3.3) | 1.3 (0.5 to 2.1) | 3.7 (2.5 to 5.0) |
| Oral; patient age, yr | |||||
| < 50 | 7.4 (−14.5 to 34.9) | 1.4 (0.4 to 2.3) | 1.9 (1.4 to 2.4) | 2.6 (2.2 to 3.0) | 1.3 (−0.2 to 2.9) |
| 50–59 | 11.8 (−5.5 to 32.3) | 0.4 (−0.3 to 1.1) | 1.1 (0.4 to 1.9) | 3.0 (2.3 to 3.6) | 6.9 (3.7 to 10.2) |
| 60–69 | 14.5 (−1.9 to 33.6) | −0.7 (−1.7 to 0.3) | 2.3 (1.3 to 3.3) | 2.9 (2.4 to 3.5) | 9.4 (6.5 to 12.4) |
| 70–79 | 16.1 (1.9 to 32.2) | −0.4 (−1.1 to 0.2) | 1.7 (1.2 to 2.2) | 3.3 (3.0 to 3.7) | 11.0 (8.7 to 13.4) |
| ≥ 80 | 13.8 (0.9 to 28.3) | −1.4 (−2.4 to −0.3) | 2.5 (1.5 to 3.5) | 3.1 (2.7 to 3.5) | 9.2 (7.0 to 11.5) |
| Intravenous/other; patient age, yr | |||||
| < 50 | 2.0 (−14.0 to 20.9) | 1.4 (0.4 to 2.3) | 0.3 (−0.7 to 1.4) | −0.5 (−1.1 to 0.2) | 0.8 (−0.2 to 1.8) |
| 50–59 | 2.2 (−9.3 to 15.2) | 0.4 (−0.3 to 1.1) | 0.6 (−0.3 to 1.6) | 0.1 (−0.6 to 0.7) | 1.2 (0.2 to 2.1) |
| 60–69 | 3.4 (−5.4 to 12.9) | −0.7 (−1.7 to 0.3) | 1.5 (0.5 to 2.6) | 1.1 (0.7 to 1.6) | 1.4 (0.5 to 2.4) |
| 70–79 | 6.5 (−3.6 to 17.6) | −0.4 (−1.1 to 0.2) | 1.7 (1.2 to 2.2) | 3.8 (3.3 to 4.3) | 1.3 (0.5 to 2.0) |
| ≥ 80 | 5.8 (−10.3 to 24.8) | −1.4 (−2.4 to −0.3) | 2.4 (1.5 to 3.4) | 4.4 (3.0 to 5.9) | 0.3 (−0.6 to 1.1) |